Delivery Order SPE2DB24D3014-SPE2DB25FKUBL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $36,218.76 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors. The contract, awarded July 18, 2025, with an ultimate completion date of July 21, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen auto-injectors on July 23, 2025. This firm fixed-price delivery order, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 24, 2025. Dupixent (dupilumab) is a biologic medication indicated for treating atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a $20,290.04 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,862.39 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a $16,346.89 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of July 28, 2025. This firm fixed-price contract, which was competitively awarded without set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through...
- The Defense Logistics Agency awarded a delivery order valued at $7,646.70 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on July 24, 2025, with completion scheduled for July 25, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat eczema, asthma, and other...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being fulfilled from AmerisourceBergen's place of business in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a $61,377.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 21, 2025, with completion targeted for July 22, 2025. This non-set-aside contract represents a child delivery order executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. Dupixent is a specialty...
- The Defense Logistics Agency awarded a delivery order valued at $11,651.25 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitive award, which carries no set-aside designation, is issued under firm fixed pricing and represents a child order to AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUBLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,158.44 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed-price, non-set-aside delivery order represents a routine pharmaceutical procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion and extending through December 2026. Dupixent is a biologic medication used to treat eczema, asthma, and allergic conditions, and its procurement through this channel supports the military's pharmaceutical supply needs for servicemembers and beneficiaries. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and primary vendor for federal medical procurement. The company's DLA prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling supply of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. This delivery order exemplifies the company's role as a critical pharmaceutical supplier within the military's medical supply chain, fulfilling routine medication requirements through competitive, firm fixed-price transactions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.2k | 7/22/25 |